Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07285421

Renal and Vascular Phenotypic Characterization of Patients With Enamel Renal Syndrome Due to a Pathogenic Variant of the FAM20A Gene and Pathophysiological Study of Ectopic Calcifications

In the research, the investigators will characterize the renal and vascular damage and look for factors favoring the formation of calcification induced by enamel renal syndrome.

Patients will undergo four investigations, as part of their routine care, to assess their renal impairment. Each investigation will require a day in the Physiology Department of the George Pompidou European Hospital.

The 4 tests are designed to

* precisely measure your renal filtration capacity, * evaluate your body's calcium and phosphate regulation, * evaluate your capacity to regulate the elimination of water from the body * assess your body's ability to regulate "acid" intake. As part of the research, an additional 20 ml blood sample and a urine sample will be taken during the other samples taken as part of routine care.

Healthy volunteers will undergo blood and urine tests, dental X-rays and renal ultrasound. For healthy volunteers, the aim of the dental X-ray and renal ultrasound is to check that there are no dental or renal abnormalities, so as to rule out not only email-rein syndrome, but also any dental or renal abnormalities that might resemble it. The aim of blood and urine sampling is to measure various molecules that promote calcification or inhibit the calcification process, so as to be able to compare results obtained in healthy subjects with those obtained in patients with enamel renal syndrome. Each healthy subject will be selected to be matched by age and sex to each of the patients included in the study.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

HEGP - clinical investigation center, Paris, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed patient who does not object to participating in the study
  • Age ≥ 18 years
  • Be affiliated to a social security scheme or be a beneficiary of such a scheme
  • Able to understand the interest and constraints of the study
  • Suffering from enamel-renal syndrome with a proven pathogenic variant of FAM20A

Exclusion criteria

  • Pregnancy
  • Breast-feeding
  • Simultaneous participation in a therapeutic trial
  • Patient under guardianship or curatorship
  • Patient under court protection or family guardianship
  • Patient under AME
  • Enamel-renal syndrome with pathogenic variation in a gene other than FAM20A

Treatment and study plan

urinary proteome

Diagnostic Test

Volume 2 ml, with protease inhibitor made one time for each arm of the protocol

urinary metabolome

Diagnostic Test

Sample collected once in the protocol for each arm.

Evaluation of plasma mineralization factors

Diagnostic Test

Complementary plasma analysis during another blood sample collection for both arms

Other names: Propensity score, Osteoprotegerin, dp-uc MGP, Fetuin A

Renal ultrasound

Diagnostic Test

Verification of normal renal morphology, absence of nephrocalcinosis

dental panoramic x-ray

Radiation

Verification of normal dentition

Blood and urine minimal biology

Biological

Fasting blood: creatinine, blood ions (Na + K + Cl + CO2 + Proteins), calcium, phosphate, CBC (Complete Blood Count), liver function tests, lipid profile); Morning fasting urine: creatinine, calcium, phosphate, protein, urinalysis (ECBU)

Primary outcomes

  1. Glomerular filtration rate

    Time frame: Up to 18 months

    Glomerular filtration rate measurement by measure of renal 99mTc-DTPA clearance

Secondary outcomes

  1. Comparison of urine proteome between patients and healthy volunteers

    Time frame: Up to 18 months

    Identification of candidate mechanisms to approach the pathophysiology of ectopic calcifications through the study of the urinary proteome

  2. Maximal urine osmolality

    Time frame: Up to 18 months

    Evaluation of water regulation by water deprivation test, urine collection after deprivation.

  3. Level of dp-uc MGP

    Time frame: Up to 18 months

    Identification of candidate mechanisms for approaching the pathophysiology of ectopic calcifications by assaying plasma inhibitors of biomineralization.

  4. Level of Fetuin A

    Time frame: Up to 18 months

    Identification of candidate mechanisms for approaching the pathophysiology of ectopic calcifications by assaying plasma inhibitors of biomineralization.

  5. Level of Osteoprotegerin

    Time frame: Up to 18 months

    Identification of candidate mechanisms for approaching the pathophysiology of ectopic calcifications by assaying plasma inhibitors of biomineralization.

  6. Propensity score

    Time frame: Up to 18 months

    Identification of candidate mechanisms for approaching the pathophysiology of ectopic calcifications by assaying plasma inhibitors of biomineralization.

  7. Ammonium chloride urine flow

    Time frame: Up to 18 months

    Urine collection to evaluate the acid regulation after oral ammonium chloride load test.

  8. calciuria rate

    Time frame: Up to 18 months

    Urine collection in order to evaluate calcium regulation.

  9. Ratio TmPi/DFG

    Time frame: Up to 18 months

    Blood and urine collection in order to evaluate phosphate regulation

  10. Calcium score

    Time frame: Up to 18 months

    Thoracic, abdominal and pelvic scan perform in order to evaluate vascular calcium content.

Study contacts

Contact information is provided by the study sponsor or research team.

Cléo Bourgeois

CONTACT

[email protected]

0156095638 ext. +33

Elise Bouderlique, MD

CONTACT

[email protected]

0156092866 ext. +33

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Fondation Université de Paris
  • Institut Necker Enfants Malades
  • Université de Liège

Registry information

Acronym: FAM-Cal

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Dec 16, 2025
Registry last updated
Dec 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.